임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 3상모집 중단 (진행 중)· Plaque PsoriasisA Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Arthritis, PsoriaticA Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Leukemia, Myeloid, AcuteA Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Depressive Disorder, MajorA Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Relapsed or Refractory Multiple MyelomaA Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· X-Linked Retinitis PigmentosaA Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Multiple MyelomaA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Alzheimer DiseaseA Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
리드: 얀센(J&J)
- 단계 미표기모집 중단 (진행 중)· Prevention of Venous ThromboembolismAn Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
협력: 얀센(J&J)
- 1상모집 중단 (진행 중)· Multiple MyelomaA Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Non-Muscle Invasive Bladder NeoplasmsA Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Plaque PsoriasisA Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Plaque PsoriasisA Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Colitis, UlcerativeA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Relapsed or Refractory B Cell Non-Hodgkin LymphomaA Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Plaque PsoriasisA Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Multiple MyelomaA Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· High-Risk de Novo Multiple MyelomaTeclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
협력: 얀센(J&J)
- 단계 미표기모집 중단 (진행 중)· Inherited Retinal DiseasesGlobal Patient Registry of Inherited Retinal Diseases
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Metastatic Castrate-sensitive Prostate CancerA Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
리드: 얀센(J&J)
- 1/2상모집 중단 (진행 중)· Lung CancerAmivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
협력: 얀센(J&J)
- 2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungPremedication to Reduce Amivantamab Associated Infusion Related Reactions
리드: 얀센(J&J)
- 1/2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Atrial FibrillationA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
리드: 얀센(J&J) · 협력: BMS
- 3상모집 중단 (진행 중)· Relapsed or Refractory Multiple MyelomaA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Ischemic Stroke; Ischemic Attack, TransientA Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
리드: 얀센(J&J) · 협력: BMS
- 1/2상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Multiple MyelomaA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Leukemia, Myeloid, AcuteA Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Colitis, UlcerativeA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Colitis, UlcerativeA Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Arthritis, JuvenileA Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
리드: 얀센(J&J)
- 1/2상모집 중단 (진행 중)· Lymphoma, Non-HodgkinA Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Advanced or Metastatic Non-small Cell Lung CancerA Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· Crohn's DiseaseA Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· MyositisA Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Relapsed/ Refractory Multiple MyelomaA Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 2상모집 중단 (진행 중)· AmyloidosisA Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Crohn DiseaseA Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell LungA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Crohn DiseaseA Long-term Extension Study of Ustekinumab in Pediatric Participants
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Multiple MyelomaA Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Arthritis, PsoriaticGuselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Multiple MyelomaA Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
리드: 얀센(J&J)
- 4상모집 중단 (진행 중)· Arthritis, PsoriaticA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
리드: 얀센(J&J)
- 단계 미표기모집 중단 (진행 중)· Arthritis, PsoriaticA Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
리드: 얀센(J&J)
- 3상모집 중단 (진행 중)· Multiple MyelomaA Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
리드: 얀센(J&J)
- 1상모집 중단 (진행 중)· Prostatic NeoplasmsA Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
리드: 얀센(J&J)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.